Maxim Group Issues Positive Forecast for Novogen (NASDAQ:KZIA) Stock Price

Novogen (NASDAQ:KZIA) had its target price increased by Maxim Group from $15.00 to $20.00 in a report issued on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

Other research analysts also recently issued reports about the company. Wall Street Zen raised Novogen from a “sell” rating to a “hold” rating in a research note on Friday, September 5th. HC Wainwright raised Novogen from a “buy” rating to a “strong-buy” rating and set a $13.00 price target on the stock in a research note on Thursday, July 10th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the company’s stock. According to MarketBeat, Novogen has a consensus rating of “Strong Buy” and a consensus target price of $16.50.

Novogen Price Performance

Shares of KZIA opened at $6.31 on Thursday. Novogen has a 52-week low of $2.86 and a 52-week high of $39.05. The business’s 50 day moving average price is $7.92 and its two-hundred day moving average price is $6.33.

About Novogen

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3.